BREAKING NEWS
Source: Medical News - SARS-C0V-2 -Cancer  Feb 24, 2022  3 months ago
BREAKING! Research Reveals That TMPRSS2, An Endothelial Cell Surface Protein That Is Involved In SARS-CoV-2 Cell Entry, Is Also A Tumor Suppressor!
17196 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
BREAKING! Research Reveals That TMPRSS2, An Endothelial Cell Surface Protein That Is Involved In SARS-CoV-2 Cell Entry, Is Also A Tumor Suppressor!
Source: Medical News - SARS-C0V-2 -Cancer  Feb 24, 2022  3 months ago
A startling new research finding by scientist from Jiangsu Cancer Hospital-China and China Pharmaceutical University has revealed that the cell surface protein TMPRSS2 (Transmembrane Serine Protease 2) which plays a key role for SARS-CoV-2 cell entry is also a tumor suppressor!


 
The study findings bring along worrisome implications about the possible correlation between lung cancer, pneumonia and SARS-CoV-2 coronavirus infections.
 
The TMPRSS2, a key molecule for SARS-CoV-2 invading human host cells, has an association with cancer. However, its association with lung cancer remains unexplored.
 
The study team, in five lung adenocarcinoma (LUAD) genomics datasets, explored associations between TMPRSS2 expression and immune signatures, tumor progression phenotypes, and clinical prognosis in LUAD by the bioinformatics approach.
 
The study fining showed that TMPRSS2 expression levels correlated negatively with the enrichment levels of both immune-stimulatory and immune-inhibitory signatures, while they correlated positively with the ratios of immune-stimulatory/immune-inhibitory signatures. It indicated that TMPRSS2 levels had a stronger negative correlation with immune-inhibitory than with immune-stimulatory signatures. TMPRSS2 downregulation correlated with increased proliferation, stemness, genomic instability, tumor progression, and worse survival in LUAD.
 
The study findings further validated that TMPRSS2 was downregulated with tumor progression in the LUAD dataset the team collected.
 
In vitro and in vivo experiments verified the association of TMPRSS2 deficiency with increased tumor cell proliferation and invasion and antitumor immunity in LUAD. Moreover, in vivo experiments demonstrated that TMPRSS2-knockdown tumors were more sensitive to BMS-1, an inhibitor of PD-1/PD-L1.
 
The study findings show that TMPRSS2 is a tumor suppressor, while its downregulation is a positive biomarker of immunotherapy in LUAD. The study data provides a link between lung cancer and pneumonia caused by SARS-CoV-2 infection.
 
The study findings were published on a preprint server: Research Square, and is currently being peer reviewed. https://www.researchsquare.com/article/rs-740479/v3
 
The study findings will be published in a weeks’ time in the peer reviewed Journal of Translational Medicine.
 
The SARS-CoV-2 has been shown to affect cancer patients at a higher rate than healthy people.
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7694326/
 
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8302962/
 
https://www.frontiersin.org/articles/10.3389/fmolb.2021.643004/full
 
The role played by the host enzyme TMPRSS2 in infection and cancer is the focus of this study that suggests the gene encoding this molecule is a tumor suppressor gene.
 
It is already known via many earlier studies that the transmembrane serine protease TMPRSS2 is key to the cell entry of SARS-CoV-2. The vir us accomplishes host cell attachment and invasion via its spike glycoprotein. The S1 subunit binds the angiotensin-converting enzyme 2 (ACE2) host cell receptor, undergoing a conformational change that exposes the S2 subunit. This achieves membrane fusion and viral endocytosis, following which the virus undergoes replication and transcription to form new viral particles.
 
Transmembrane Serine Protease 2 or TMPRSS2 is found at higher levels in many tumors, including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).
 
An earlier study postulated that TMPRSS2 acted as a tumor suppressor and is downregulated in LUAD tissue compared to normal tissue. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01209-2
 
The study team in this present research examined the associations between the level of TMPRSS2 expression and the immune phenotype in five LUAD cell types ie CD8+ T cells, natural killer (NK) cells, CD4+ T regulatory cells (Tregs), myeloid-derived suppressor cells (MDSCs), and PD-L1.
 
The study team also looked at oncogenic pathway activity in association with TMPRSS2 expression, as well as its link with tumor phenotype, genomic characteristics, and the outcome.
 
Corresponding author, Dr Xiaosheng Wang, a professor of oncology at China Pharmaceutical University told Thailand Medical News, “The study findings shockingly showed that TMPRSS2 expression was negatively correlated with the presence of all five types of immune cells. CD8+ T cells, as well as NK cells, are involved in antitumor immunity via the adaptive and innate arms, and the levels of both were increased with low levels of TMPRSS2 expression.”
 
Furthermore, immune cytolytic activity was also inversely related to TMPRSS2 expression, and so was PD-L-1. Meanwhile, CD4+ Tregs and MDSC infiltration, which denote tumor immunosuppression, showed a negative correlation with TMPRSS2. Overall, low levels of this molecule indicate high immune infiltration in LUAD.
 
It was also found that the ratio of CD8+ T cells/PD-L1, representing immune-stimulatory and immune inhibitory cells, respectively, were positively associated with TMPRSS2 expression, showing that the latter falls more steeply with immunosuppressive phenotypes.
 
Interestingly, the same negative correlation was present with cell cycle, mismatch repair, and other related signaling pathways.
 
The tumor proliferation marker MKI67 was also increased with low TMPRSS2 expression, indicating stemness of the tumor cell and therefore increased chances of a poor outcome. With low levels of this marker, TMPRSS2, LUAD tumors were more advanced in stage and larger in size, and thus the survival odds were lower.
 
Past studies have established that the presence of EGFR mutations is associated with a better prognosis compared to the wild-type EGFR in LUAD. The former was associated with higher TMPRSS2 expression than the latter. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228925
 
Also, another favorable prognostic marker is TRU (terminal respiratory unit), which was also inversely associated with TMPRSS2 levels. 
 
Typically, genomic instability is an indicator of a poorer prognosis in cancer since it is associated with increased initiation, progression, and invasion. Either mutation numbers, aneuploidy, or copy numbers of somatic chromosomes may be involved. TMPRSS2 downregulation is linked to higher levels of gene instability.
 
It was also found that homologous recombination deficiency (HRD) promotes such instability and has been found to be higher with low TMPRSS2 expression.
 
Harmful mutations were previously found in nine DDR (DNA damage response) pathways in TCGA (The Cancer Genome Atlas) cancers.
 
This present study classified LUAD into those with and without mutations in each pathway. This showed that TMPRSS2 levels were markedly lower in the tumors with mutated pathways for seven of the pathways, such as damage sensing, excision repair of nucleotides and of bases, mismatch repair, and homologous recombination.
 
Transmembrane Serine Protease 2 or TMPRSS2 expression was also lower in cases when DDR molecules were expressed at higher levels, this being the marker of increased genomic instability.
 
It was also found that several other genes sets dealing with the cell cycle, p53 signaling, mismatch repair, and homologous recombination pathways were all upregulated with lower TMPRSS2 expression levels. Six gene modules were highly enriched in LUADs with high TMPRSS2 levels, conversely forming an ECM signature that is central to cancer progression.
 
The study findings were validated using in vitro human cell lines and in vivo mouse models. In other words, TMPRSS2 knockdown led to significantly higher tumor cell proliferation and invasiveness in the cell model and larger progressive tumors in the mouse experiments.
 
Detailed bioinformatics also showed that immune infiltration in LUAD occurred more frequently with lower TMPRSS2 expression. At the same time, MHC class I genes were expressed at higher levels, and NK cells showed higher proliferation rates. In vivo too, CD8+ T cells and NK cells showed an increase in infiltration as well as higher activation levels, with TMPRSS2 knockdown, as signified by the production of TNF-α and IFN-γ. Exhaustion markers in these tumors were increased simultaneously.
 
The PD-L1 is a biomarker of the tumor response to immune checkpoint inhibitors in cancer treatment. With TMPRSS2 knockdown, tumor volume reduced more than that of wild-type tumors following treatment with one such inhibitor. This agrees with the finding that PD-L1 expression increases with the knockdown of TMPRSS2.
 
Furthermore, in the same treatment scenario, both CD8+ T cells and NK cells infiltrating the tumor showed higher activity levels in TMPRSS2 knockdown tumors than in wild-type tumors. The inhibitor seems to enhance immune-mediated tumor cell elimination by blocking exhaustion of CD8+ and NK tumor-infiltrating lymphocytes in the LUAD with TMPRSS2 knockdown.
 
Worrisome Implications
 
Transmembrane Serine Protease 2 or TMPRSS2 molecule jumped into the limelight with the SARS-CoV-2 outbreak as it was essential for the virus successful entry into the target host cell.
 
The study findings however show that in LUAD, the most common type of lung cancer, TMPRSS2 is a tumor suppressor. With low levels of this enzyme, tumor-inducing pathways show enhanced activity.
 
Any downregulation of TMPRSS2 and we will witness tumor cell proliferation increases with stem cell characteristics, genomic instability, and tumor stage advancement. The odds of survival also dips. Experiments in vitro and in vivo confirmed the key role played by TMPRSS2 in LUAD proliferation and invasiveness.
 
The TMPRSS2 molecule appears to be lowest when immune inhibition phenotypes are present vs. immunostimulatory signatures. This could explain why patients with LUAD showing TMPRSS2 deficiency have worse outcomes.
 
Importantly in vivo experiments demonstrated the increased sensitivity of TMPRSS2-knockdown tumors to the PD-1/PD-L1 inhibitor, making the former a positive marker of immunotherapy in this disease.
 
Considering the tumor suppressor activity of TMPRSS2, its inhibition may tend to promote increased tumor growth and invasiveness. Surprisingly, non-smokers with LUAD had higher rates of infection with SARS-CoV-2 than smokers with this tumor.
 
The study team concluded, “TMPRSS2 is a tumor suppressor in LUAD, as evidenced by its downregulation correlated with increased genomic instability, tumor progression, and unfavorable clinical outcomes in LUAD. However, TMPRSS2 downregulation is a positive biomarker of immunotherapy for LUAD. Our data provide implications in the connection between lung cancer and pneumonia caused by SARS-CoV-2 infection.”
 
Further studies are also needed to see if SARS-CoV-2 infections also further increase the risk of cancers and tumors as a result of the depletion of TMPRSS2 molecules  being used for viral entry.
 
For more on SARS-CoV-2 and TMPRSS2, keep on logging to Thailand Medical News.
 
 

MOST READ

Aug 13, 2020  2 years ago
Source: Supplements For COVID-19
Feb 05, 2020  2 years ago
Source : Thailand Medical news